Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation

The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a “difficult-to-manage” state with available treatments. The aim of this paper...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Uz, B., Bektas, O., Eliacık, E., Goker, H., Erbilgin, Y., Sayitoglu, M., Sayinalp, N., Aksu, S., Buyukasik, Y., Ozcebe, O., Haznedaroglu, I. C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3420724/
https://ncbi.nlm.nih.gov/pubmed/22937303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/263725
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares